Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.
about
Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.Identification of oxidation sites and covalent cross-links in metal catalyzed oxidized interferon Beta-1a: potential implications for protein aggregation and immunogenicityOxidation of therapeutic proteins and peptides: structural and biological consequences.Nebulization as a delivery method for mAbs in respiratory diseases.A snapshot of biologic drug development: Challenges and opportunities.Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges.Forced degradation studies: current trends and future perspectives for protein-based therapeutics.Why the Immune System Should Be Concerned by Nanomaterials?Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting.The immunogenicity of antibody aggregates in a novel transgenic mouse model.Nanoparticulate Impurities in Pharmaceutical-Grade Sugars and their Interference with Light Scattering-Based Analysis of Protein Formulations.The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling.Quantitative laser diffraction method for the assessment of protein subvisible particlesRaman spectroscopy characterization of antibody phases in serum.AlphaScreen-based homogeneous assay using a pair of 25-residue artificial proteins for high-throughput analysis of non-native IgG.Probing structurally altered and aggregated states of therapeutically relevant proteins using GroEL coupled to bio-layer interferometrySmall amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics.Nanoparticulate Impurities Isolated from Pharmaceutical-Grade Sucrose Are a Potential Threat to Protein Stability.Recombinant Proteins and Monoclonal Antibodies.In vivo fluorescence imaging of IgG1 aggregates after subcutaneous and intravenous injection in mice.Immunogenicity of protein aggregates of a monoclonal antibody generated by forced shaking stress with siliconized and nonsiliconized syringes in BALB/c mice.The Impact of Inadequate Temperature Storage Conditions on Aggregate and Particle Formation in Drugs Containing Tumor Necrosis Factor-Alpha Inhibitors.Correcting the Relative Bias of Light Obscuration and Flow Imaging Particle Counters.Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
P2860
Q36257660-0A889AC6-B675-44F8-8D32-AC1DB02BC226Q37078660-F9663A1E-8946-479A-8C34-1532636552D0Q38142887-E6B4D04C-F03E-4B73-BFA3-8C97C805ECBEQ38306677-324C84BF-87D6-42F0-8EB7-EAB94088D7BAQ38651271-8D2FA7D2-64D5-4B62-A799-8391BC6B477DQ38781432-52468E22-7D67-42C4-89A0-0EEA6D8B7A94Q38798188-EAE13113-6EC7-45AB-A2AD-1C71F8403237Q38855242-B4C03512-F778-4C7C-86AE-6928EE5833D3Q39336982-F710E50B-C7E1-438E-ABC1-A7E2083A9557Q40119636-2462689B-281B-4F8F-AB46-884C1B27CEEFQ40143552-9D8DA19B-E0F3-4FF3-957F-AA20FCD95FACQ40514614-25A9AA6A-559E-42DE-8CC5-5F34D9E8ABEFQ41353938-80348770-4E21-434D-8644-6975D6D21ED3Q41512850-C2218BF2-55BC-4DA2-8D34-5D101A3201B6Q41558985-72C36E42-5FC3-4D8C-957A-393A00357BAAQ41953123-BBF7CAFD-8FCC-44E8-8A49-48F53C7902CFQ41965705-63CCAB4D-56C2-467B-942D-68FCAFEDA15FQ42177409-7911EC5B-EC8C-4040-BF98-6A56947E6343Q42367805-1697844D-B9A5-40EC-965A-FF9C71ED8F77Q42553159-C300A64B-7DCA-4603-B644-49E25566F1A2Q44285833-5634307B-C1CC-4EA7-B853-7375491CE687Q46275499-A5AEDFB7-0506-4B3C-B2AC-EE0CC813C229Q47602370-60C75890-44E0-4392-83B4-2A1E11DB2FDDQ47770763-CC25C512-CD47-4FFA-916F-FD266F1981F3Q48238341-8E1ADD15-EEE6-4C84-9D21-4BF8CA9C62B2Q48502841-C4EAA71B-AD4E-4496-B998-FEA187461956Q48718103-C473D8DC-FB95-4BD8-8DC9-20D844563527Q50508037-09AD07AB-EDDF-4B3E-BC59-0FA4383949F9
P2860
Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Immunogenicity of different st ...... mune tolerant transgenic mice.
@ast
Immunogenicity of different st ...... mune tolerant transgenic mice.
@en
type
label
Immunogenicity of different st ...... mune tolerant transgenic mice.
@ast
Immunogenicity of different st ...... mune tolerant transgenic mice.
@en
prefLabel
Immunogenicity of different st ...... mune tolerant transgenic mice.
@ast
Immunogenicity of different st ...... mune tolerant transgenic mice.
@en
P2093
P2860
P356
P1476
Immunogenicity of different st ...... mune tolerant transgenic mice.
@en
P2093
Abdul Hafid Basmeleh
Andhyk Halim
Huub Schellekens
Vasco Filipe
Vera Brinks
Wim Jiskoot
P2860
P304
P356
10.4161/MABS.22066
P577
2012-09-05T00:00:00Z